Biogen to Invest $2 Billion in RTP Manufacturing

As Biogen celebrates its 30th anniversary in the Research Triangle Park (RTP), the company says it will boost its North Carolina operations with a $2 billion investment in manufacturing facilities.

Since opening its first facility in 1995, Biogen has invested roughly $10 billion in its RTP footprint, including more than $3 billion in recent years, company officials said.

The fresh funding aims to support late-stage clinical trials and boost manufacturing capabilities at RTP’s two campuses. Planned upgrades include:

  • Expanded antisense oligonucleotide (ASO) infrastructure
  • New fill-finish lines for both clinical and commercial supply
  • Updated automation and artificial intelligence systems

“We are proud of our longstanding commitment to manufacturing innovation, investment, and collaboration with the Research Triangle Park community,” said Nicole Murphy, head of pharmaceutical operations and technology for Biogen.

Murphy noted the upgrades will help “modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated life sciences talent in North Carolina.”

Biogen is a top employer in the state’s biotech sector and ranks among the top five in biopharma. It currently employs more than 1,500 staff and 400 contractors across Wake and Durham counties.

The company says more than 90% of its innovator medicines undergo manufacturing and quality control in the U.S.

On RTP’s campuses, Biogen operates seven manufacturing plants, with an eighth set to open in late 2025. These sites support various drug types and include advanced quality-control labs. Globally, Biogen maintains additional facilities in Switzerland and Europe, with plans to centralize some fill-finish operations in Ireland.

Founded in 1978, Biogen is a pioneer in biotechnology, focusing on treatments that address serious diseases using advanced biological approaches. With businesses rooted in human biology and multiple therapeutic modalities, the company says it strives to balance ambition with strong financial returns.

Get Connected

Wes Platt
Author: Wes Platt

Lead storyteller. Game designer and journalist. Recovering Floridian. Email: southpointaccessnews@gmail.com.

Leave a Reply

Discover more from Southpoint Access

Subscribe now to keep reading and get access to the full archive.

Continue reading